2018, Jan. 13-15: Diagnostic Cytopathology Charleston, SC
January 13-15, 2018
16 CMEs / 13.5 SAMs
Cytopathologists, in the era of genomic and personalized medicine, are expected to "do more with less" in specimen procurement, sample validation for diagnostic integrity, selection of ancillary tests (including molecular studies) and providing conduits to genetic testing. Small samples collected by image-guided fine needle aspiration biopsy, EBUS and mini-biopsies, touch preparations and core extraction challenge professional expertise and are determinants of therapeutic pathways and patient outcomes.
Patient care is optimized when cytopathologists communicate their diagnostic findings effectively to clinicians and intelligibly to patients. Systematic reporting systems for thyroid, salivary gland and urine are included in this program to enhance information transfer.
Molecular diagnostics are explored in general, with focus on HPV testing in head and neck cancers and as components of cervical cancer screening and prevention.
Challenge areas in diagnostic cytopathology are given particular attention – pancreas and kidney pathology is evolving in criteria, classification and nomenclature, and renal lesions have particular genomic and immunohistochemical profiles.
FNA biopsy has tremendously facilitated the evolution of patient-centered care and assuring cytopathologists of their place on health care delivery teams. Empathy and communication are important elements. Quality initiatives are guardians of patient care and lessons learned from the CAP's laboratory accreditation program will be discussed.
Whether you're a committed cytopathologist or a pathologist confronted with cytopathology in your general practice, this course will update your knowledge and stimulate your comprehension and confidence.
Charleston is a fantastic venue, a city of art, architecture, historical significance, culinary experiences, and exuberant people.
- Learn how therapeutically-useful information can be extracted from cellular samples and small biopsies utilizing cytomorphological, molecular and genetic techniques
- Enhance communication through the understanding and use of systematic, standardized, organ-based reporting systems
- Explore difficult areas of cytopathologic diagnosis in pancreas and kidney
- Understand the role of FNA biopsy in the evolution of empathetic patient-centered care
- Develop methods of practice improvement and quality improvement
- Discover that cytopathology is a community of diagnosticians dedicated to improvement of patient outcomes through specialized expertise
Ritu Nayar, MBBS, M.D.
- Sinchita Roy-Chowdhuri, M.D., Ph.D.
University of Texas MD Anderson Cancer Center
- William Faquin, M.D., Ph.D.
Harvard Medical School
- David B. Kaminsky, M.D., FIAC
United States and Canadian Academy of Pathology
- Sara E. Monaco, M.D.
University of Pittsburgh Medical Center
- Edward Stelow, M.D.
University of Virginia Health System
- Eva M. Wojcik, M.D.
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians can earn a maximum of 16 AMA PRA Category 1 Credits™ by participating in the CME activities within the 2018 Diagnostic Cytopathology Course.
USCAP is approved by the American Board of Pathology (ABP) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABP requirements for Maintenance of Certification (MOC). Registrants must take and pass the post-test in order to claim SAMs credit.
Physicians can earn a maximum of 13.5 SAM credit hours.
USCAP records courses for future educational purposes. By registering for this conference, you consent that your likeness may be used by USCAP.